Wednesday, 3 July 2013

Global Pharma Report: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022

GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines Australia Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

To Read The Complete Report with  TOC :-

GlobalData believes that relative patient share for the three MenC conjugate vaccines available in Australia will remain unchanged for the duration of the forecast period because Nuron Biotechs Meningitec, Novartis Menjugate, and Baxters NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Australia and therefore is not expected to change drastically during the forecast period.


  • Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Australia including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Australia from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Australia Meningococcal Vaccines market.

To Buy a Copy Of This Report:-

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Australia

M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

No comments:

Post a Comment